Sweden stimulates biotech start-ups:
This article was originally published in Clinica
Executive Summary
The Karolinska Institute and the Swedish insurance company, SPP, have established a new venture capital fund to invest in R&D projects in the medical, biotechnology and medical technology fields. The Karolinska Investment Fund, of around SKr500 million ($61 million), is one of the first in Sweden to involve an academic institute linking up with an investment group. The fund will invest primarily in research projects at the Karolinska Institute and other medical institutions, universities and colleges in Sweden, thereby providing support for commercialisation of such projects. It is not restricted to investing in the institute or in Sweden, and although its main focus is on early-stage research, it may consider investing in more advanced projects and companies.